393 related articles for article (PubMed ID: 34877360)
1. Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation.
Liu C; Wang M; Xu C; Li B; Chen J; Chen J; Wang Z
J Immunol Res; 2021; 2021():8970173. PubMed ID: 34877360
[TBL] [Abstract][Full Text] [Related]
2. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
Zeng Z; Yang B; Liao Z
Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
[TBL] [Abstract][Full Text] [Related]
3. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
[TBL] [Abstract][Full Text] [Related]
4. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
5. Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma.
Lin E; Liu X; Liu Y; Zhang Z; Xie L; Tian K; Liu J; Yu Y
Front Immunol; 2021; 12():653358. PubMed ID: 33746989
[TBL] [Abstract][Full Text] [Related]
6. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma.
Yang H; Zhao L; Zhang Y; Li FF
Cancer Med; 2021 Aug; 10(16):5696-5711. PubMed ID: 34258887
[TBL] [Abstract][Full Text] [Related]
8. Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications.
Del Conte A; De Carlo E; Bertoli E; Stanzione B; Revelant A; Bertola M; Spina M; Bearz A
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743275
[TBL] [Abstract][Full Text] [Related]
9. Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses.
Tian J; Quek C
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673829
[TBL] [Abstract][Full Text] [Related]
10. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
11. Advances in Osteosarcoma.
Panez-Toro I; Muñoz-García J; Vargas-Franco JW; Renodon-Cornière A; Heymann MF; Lézot F; Heymann D
Curr Osteoporos Rep; 2023 Aug; 21(4):330-343. PubMed ID: 37329384
[TBL] [Abstract][Full Text] [Related]
12. Normalization Cancer Immunotherapy for Melanoma.
Vesely MD; Chen L
J Invest Dermatol; 2020 Jun; 140(6):1134-1142. PubMed ID: 32092349
[TBL] [Abstract][Full Text] [Related]
13. Dilemma and Challenge of Immunotherapy for Pancreatic Cancer.
Wu J; Cai J
Dig Dis Sci; 2021 Feb; 66(2):359-368. PubMed ID: 32140943
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
Front Immunol; 2021; 12():697298. PubMed ID: 34858389
[TBL] [Abstract][Full Text] [Related]
15. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
16. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang Q; Xie B; Liu S; Shi Y; Tao Y; Xiao D; Wang W
Front Immunol; 2021; 12():773168. PubMed ID: 35003090
[TBL] [Abstract][Full Text] [Related]
17. Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors.
Ahn R; Ursini-Siegel J
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807608
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint Inhibitors in Bone Metastatic Disease in Solid Tumors.
Wytiaz V; Van Poznak C
Curr Osteoporos Rep; 2023 Aug; 21(4):323-329. PubMed ID: 37294479
[TBL] [Abstract][Full Text] [Related]
19. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
[TBL] [Abstract][Full Text] [Related]
20. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
